The still evolving US sanctions (as well as the EU and now also separate UK sanctions) continue to challenge Russia-related business. The sanctions frameworks are complex, changing, and, at times, inconsistent as well as...more
3/23/2021
/ Bureau of Industry and Security (BIS) ,
CAATSA ,
Crimea ,
Economic Sanctions ,
EU ,
Foreign Policy ,
Infrastructure ,
Office of Foreign Assets Control (OFAC) ,
Oil & Gas ,
Russia ,
SDN List ,
UK ,
UK Brexit
United States -
Various threats of further broad sanctions… triggered by ongoing negative developments and perceptions in the US-Russia relationship – though new sanctions legislation seems unlikely before the 3 Nov. US...more
10/7/2020
/ CAATSA ,
Crimea ,
Economic Sanctions ,
EU ,
Exports ,
Foreign Relations ,
Office of Foreign Assets Control (OFAC) ,
Russia ,
SDN List ,
Trade Relations ,
UK ,
UK Brexit ,
US Trade Policies
This presentation, an update to our April 2020 presentation, highlights the most recent developments and then provides a detailed overview of the relevant frameworks and their possible implications—including a focus on the...more
7/30/2020
/ CAATSA ,
Crimea ,
Economic Sanctions ,
EU ,
Foreign Policy ,
Foreign Relations ,
Office of Foreign Assets Control (OFAC) ,
Oil & Gas ,
Russia ,
SDN List ,
UK Brexit
Welcome to the third issue of our European Life Sciences Review that covers some of the most critical developments in the pharmaceutical and medical technology sectors in the last month and is produced by our life sciences...more
7/16/2016
/ Anti-Competitive ,
Anti-Corruption ,
Clinical Trials ,
Data Protection ,
EU ,
EU-US Privacy Shield ,
General Data Protection Regulation (GDPR) ,
Life Sciences ,
Medical Devices ,
Mobile Health Apps ,
Off-Label Promotion ,
Pharmaceutical Industry ,
TTIP ,
UK ,
UK Brexit ,
UK Competition and Markets Authority (CMA)
Welcome to the second issue of our EU life sciences alerter that covers some of the most critical developments in the pharmaceutical and medical technology sectors in the last month and is produced by our life sciences...more
Welcome to the first issue of our EU Life Sciences Review . It is produced by our life sciences lawyers in London, Brussels, Frankfurt, Moscow, and Paris and covers some of the most critical developments in the pharmaceutical...more
2/2/2016
/ Biotechnology ,
EU ,
European Commission ,
European Court of Justice (ECJ) ,
European Food Safety Authority (EFSA) ,
General Data Protection Regulation (GDPR) ,
Hazardous Waste ,
Life Sciences ,
Orphan Drugs ,
Personalized Medicine ,
The Patent Box ,
UK ,
Unitary Patent ,
US-EU Safe Harbor Framework